Recombinant Hyperimmune Polyclonal Antibody (GIGA-2050) in COVID-19 Patients
Status:
Recruiting
Trial end date:
2021-08-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of single ascending IV
dose administrations of GIGA-2050 in patients hospitalized with COVID-19.